Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

作者：Luis Paz‐Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Roy S. Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Alı Nahıt Şendur, Grzegorz Czyżewicz, Reyes Bernabé Caro, Ki Hyeong Lee, Melissa L. Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Jin Seok Ahn, Raffaele Califano, Tsung‐Ying Yang, Yasemi̇n Kemal, Marcus Ballinger, Vaikunth Cuchelkar, Vilma Graupner, Ya‐Chen Lin, Debasis Chakrabarti, Kamalnayan Bhatt, George Cai, Robert Iannone, Martin Reck · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)01011-6 · 被引用次数：86 · 研究领域：Lung Cancer Research Studies、Lung Cancer Treatments and Mutations、Radiopharmaceutical Chemistry and Applications